So­tio part­ners with Mer­ck to test lead can­di­date with Keytru­da; DC's KeifeRx rais­es $6M in Se­ries A — and brings on two new board mem­bers

So­tio has been on a roll late­ly.

The qui­et Czech biotech based in Prague got a mas­sive $315 mil­lion raise last week, and now the biotech an­nounced to­day that it’s joined in on a col­lab­o­ra­tion with Mer­ck to eval­u­ate a com­bo of So­tio’s lead can­di­date SOT101 with Mer­ck’s PD-1 an­ti­body Keytru­da.

The two drugs will be test­ed in pa­tients with ad­vanced/re­frac­to­ry sol­id tu­mors in a Phase II tri­al. Ac­cord­ing to So­tio’s CEO, the two drugs com­bined had al­ready shown ef­fi­ca­cy in an on­go­ing Phase I/Ib tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER